Medscape

Long-Acting Risperidone Injection

Long-acting risperidone is a suspension administered by intramuscular injection in the upper-outer gluteal area. It consists of risperidone impregnated in microspheres composed of a biodegradable, ...
Monthly Prescribing Reference

Additional injection site approved for Risperdal Consta

The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...
Yahoo Finance

Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform ...

MUMBAI, India and NAPLES, Fla., Nov. 14, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of ...
FiercePharma

New Data on INVEGA(R) SUSTENNA(R) and RISPERDAL(R) CONSTA(R) for Schizophrenia to be Presented at Major Psychiatry Meeting

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
Business Wire

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...
Drug Store News

Lupin receives FDA nod for generic Risperdal Consta

Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.
FierceBiotech

Ortho-McNeil-Janssen Pharmaceuticals, Inc. Release: FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia

TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long ...
FierceBiotech

FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder

TITUSVILLE, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that the Food and Drug ...

Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the trea…

Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), announces the listing of ...
Medscape

Long-Acting Risperidone Injection

Long-acting risperidone injection was released for marketing for the treatment of schizophrenia in the United States in October 2003. The drug was available in 45 countries as of December 2003. Steady ...
Business Wire

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

About Risperidone Extended-Release Injectable Suspension for Subcutaneous Use The extended-release subcutaneous risperidone injection is an investigational once-monthly or once-every-two-months ...